Tianjing Biotechnology and Jichuan Pharmaceutical jointly announced that the application for marketing of Yitan long-acting growth hormone has been accepted
六月清晨搅
发表于 2024-12-10 11:26:44
137
0
0
According to AI News, on December 9th, Tianjing Biotechnology and Jichuan Pharmaceutical jointly announced that the biological product marketing application (BLA) for the treatment of children with growth hormone deficiency (PGHD) with Yitan long-acting recombinant human growth hormone injection (hereinafter referred to as "Yitan long-acting growth hormone") has been approved by NMPA.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Xiaopeng Motors: Xiaopeng Huitianzheng has obtained a licensed flight certificate for the development of a fully tilt technology verification aircraft
- Novo Nordisk Ultra Long acting Insulin Global First Batch Expected Within Two Months
- Is Eli Lilly Alzheimer's medication about to be approved? Supported by FDA advisory panel, with a market value exceeding $800 billion for the first time
- The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
